Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwAL 2026 | Allogeneic transplantation in fit older adults with AML

Charles Craddock • 19 Sep 2026
iwAL 2026
Acute Myeloid Leukemia Leukemia Chemotherapy

Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, Birmingham, UK, discusses the role of allogeneic stem cell transplantation in adults over 70 years of age with acute myeloid leukemia (AML). He highlights physiological fitness and comorbidity burden rather than chronological age as key determinants of transplant suitability, supporting early donor searches and referral for fit older patients with high-risk disease. This interview took place at the 8th International Workshop on Acute Leukemias (iwAL 2026), held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Charles Craddock

Expanding donor access for allogeneic transplantation in AML
2:46
Expanding donor access for allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
1:35
Maximizing the graft-versus-leukemia effect after allogeneic transplantation in AML
Charles Craddock • 19 Sep 2026
Optimizing allogeneic transplantation through prospective randomized trials in AML
3:08
Optimizing allogeneic transplantation through prospective randomized trials in AML
Charles Craddock • 19 Sep 2026
The COSI trial: addition of thiotepa to improve outcomes in patients with AML undergoing alloSCT
1:34
The COSI trial: addition of thiotepa to improve outcomes in patients with AML undergoing alloSCT
Charles Craddock • 5 Dec 2025

Related Videos

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals